Literature DB >> 3947509

Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.

S Merry, C A Fetherston, S B Kaye, R I Freshney, J A Plumb.   

Abstract

We have investigated the mechanism of resistance to adriamycin (ADR) of 3 human glioma cell lines in culture. The cell lines had different inherent sensitivities to ADR. Verapamil increased the ADR sensitivities of the 2 most resistant cell lines (G-UVW and G-CCM) by up to 5-fold. This effect was not seen in a sensitive cell line (G-MCF). Although the accumulation of ADR in the 3 cell lines was not related to inherent sensitivity, energy deprivation or the addition of verapamil produced an increase (up to 46%) in net uptake for both G-UVW and G-CCM, but not for G-MCF. For G-UVW the ADR efflux data were consistent with an energy-dependent ADR efflux mechanism which could be inhibited by verapamil. A similar mechanism was not found for G-CCM. In this cell line verapamil may act by increasing intracellular ADR binding. These data indicate that, while inherent resistance to ADR may be multifactorial, one possible mechanism of resistance in human glioma may involve changes in drug accumulation and/or binding as has been seen in animals models. A potential clinical role for verapamil in overcoming drug resistance in human solid tumours is also indicated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947509      PMCID: PMC2001452          DOI: 10.1038/bjc.1986.18

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Symposium on cellular resistance to anticancer drugs. Introduction.

Authors:  B A Chabner; N J Clendeninn; G A Curt
Journal:  Cancer Treat Rep       Date:  1983-10

Review 2.  Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts.

Authors:  W T Beck
Journal:  Cancer Treat Rep       Date:  1983-10

3.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

4.  Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.

Authors:  T Tsuruo; H Iida; K Naganuma; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

5.  Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.

Authors:  R Ganapathi; D Grabowski
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

6.  Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.

Authors:  L M Slater; S L Murray; M W Wetzel; R M Wisdom; E M DuVall
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

7.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

8.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

Review 9.  Evidence for multidrug-resistant cells in human tumor cell populations.

Authors:  R H Shoemaker; G A Curt; D N Carney
Journal:  Cancer Treat Rep       Date:  1983-10

10.  Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.

Authors:  D Kessel; C Wilberding
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

View more
  14 in total

1.  Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin.

Authors:  R Supino; M Mariani; E Prosperi; G Parmiani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Kinetic and survival response of the M14 cell line to lonidamine associated with adriamycin or hyperthermia.

Authors:  G Starace; G Badaracco; A Bertuzzi; A Gandolfi; C Greco; M D Totaro; R Vitelli; G Zupi
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro.

Authors:  E M Gibby; O Boyse; B T Hill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Effect of mitomycin C, verapamil, and hyperthermia on human gastric adenocarcinoma.

Authors:  I B Shchepotin; R R Buras; R J Nauta; M Shabahang; S R Evans
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells.

Authors:  K R Huber; W F Schmidt; E A Thompson; A M Forsthoefel; R W Neuberg; R S Ettinger
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

7.  Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.

Authors:  M A Smith; S Merry; J G Smith; S B Kaye
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

8.  Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines.

Authors:  K Snow; W Judd
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

9.  Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil.

Authors:  S Merry; E R Courtney; C A Fetherston; S B Kaye; R I Freshney
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

10.  P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.

Authors:  S Huet; B Schott; J Robert
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.